Toggle Health Problems and D

Asthma and COPD in a few seniors greatly decreased by monthly 100,000 IU Vitamin D – RCT Feb 2021

Effect of Monthly Vitamin D Supplementation on Preventing Exacerbations of Asthma or Chronic Obstructive Pulmonary Disease in Older Adults: Post Hoc Analysis of a Randomized Controlled Trial

Nutrients 2021, 13(2), 521; https://doi.org/10.3390/nu13020521
by Carlos A. Camargo, Jr. 1,*OrcID,Les Toop 2OrcID,John Sluyter 3OrcID,Carlene M. M. Lawes 3,Debbie Waayer 3OrcID,Kay-Tee Khaw 4,Adrian R. Martineau 5 and Robert Scragg 3OrcID


This study is a subset of the following, and had only 18 people with <10 ng of vitamin D
Study did not accept people supplementing with more than 600 or 800 IU of vitamin D
Monthly 100,000 IU of vitamin D is safe (and may be better than daily) – RCT Aug 2018

Overview Asthma and Vitamin D contains

The worse the bronchial asthma, the lower the vitamin D – Jan 2017
click on chart to see the study

VitaminDWiki - Weekly, Monthly Vitamin D are typically better than daily - many studies

COPD fought by Vitamin D - many studies has the following


VitaminDWiki -Weekly, Monthly Vitamin D are typically better than daily - many studies

 Download the PDF from VitaminDWiki

Only 18 people had < 10 ng of vitamin D

Randomized controlled trials have suggested that vitamin D supplementation can prevent asthma and chronic obstructive pulmonary disease (COPD) exacerbations. For COPD, the benefit appears to be limited to individuals with baseline 25-hydroxyvitamin D (25OHD) levels <25 nmol/L. We performed a post hoc analysis of data from a randomized, double-blinded, placebo-controlled trial to investigate the effect that monthly, high-dose vitamin D supplementation (versus placebo) had on older adults with asthma and/or COPD. Specifically, we investigated whether vitamin D supplementation prevented exacerbations of these conditions.

Participants were randomly assigned either to an initial oral dose of 200,000 IU vitamin D3 followed by 100,000 IU monthly or to placebo, with an average follow-up period of 3.3 years. Among the 5110 participants, 775 had asthma or COPD at the beginning of the study, and were eligible for inclusion in this analysis. Exacerbations were defined by the prescription of a short-burst of oral corticosteroids. The mean age of the participants was 67 years old, and 56% were male. The mean baseline blood 25OHD level was 63 nmol/L; 2.3% were <25 nmol/L. Overall, we found that vitamin D supplementation did not affect the exacerbation risk (hazard ratio 1.08; 95%CI 0.84–1.39). Among those with baseline 25OHD <25 nmol/L, however, the hazard ratio was 0.11 (95%CI 0.02–0.51); p for interaction = 0.001. Although monthly vitamin D supplementation had no overall impact on risk of exacerbations of asthma or COPD, we found evidence of a probable benefit among those with severe vitamin D deficiency. View Full-Text

Created by admin. Last Modification: Sunday March 17, 2024 19:07:58 GMT-0000 by admin. (Version 9)

Attached files

ID Name Comment Uploaded Size Downloads
15826 Less than 18 people.jpg admin 28 Jun, 2021 24.94 Kb 386
15825 Asthma montlhly D.jpg admin 28 Jun, 2021 36.73 Kb 433
15824 Asthma monthly VIitamin D helped those who were low.pdf admin 28 Jun, 2021 904.48 Kb 392